Psyence BioMed Secures GMP-Compliant Ibogaine Supply Chain With African Source Platform
Psyence BioMed has completed a vertically integrated, GMP-compliant ibogaine supply chain through its PsyLabs collaboration, securing raw materials, extraction, and standardized inventory at Africa source. The platform holds ready-to-use GMP ibogaine doses and total alkaloid extracts to support global clinical research and partner programs.
1. Integrated Supply Chain
Over the past year, Psyence BioMed invested in a purpose-built platform with PsyLabs that integrates raw material sourcing in Africa, extraction, purification, and pharmaceutical production under GMP guidelines. This vertical integration ensures traceability, supply continuity, and ethical sourcing aligned with sustainability goals.
2. GMP-Compliant Inventory
The company currently holds standardized, stabilized, and GMP-compliant ibogaine doses in inventory ready for immediate distribution to research and clinical programs. It also maintains total alkaloid extracts to accommodate diverse therapeutic development needs.
3. Market Advantage and Partnerships
With limited global access to pharmaceutical-grade ibogaine, this platform positions Psyence BioMed as the sole licensed supplier at the source. The infrastructure supports partnerships across early-stage research, clinical development, and eventual commercialization of ibogaine-based therapies.